JAMA dermatology最新文献

{"title":"Use of Nemolizumab in Refractory Scrotal Dysesthesia.","authors":"Walter Liszewski","doi":"10.1001/jamadermatol.2025.1480","DOIUrl":"10.1001/jamadermatol.2025.1480","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"886-887"},"PeriodicalIF":11.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Climate Conditions, Weather Changes, and Air Pollutants and Atopic Dermatitis: A Meta-Analysis.","authors":"Megan Park, Samiha T Mohsen, Talia Katz, Siddhartha Sood, Sheena Maureen T Sy, Bram Rochwerg, Aaron M Drucker","doi":"10.1001/jamadermatol.2025.1790","DOIUrl":"10.1001/jamadermatol.2025.1790","url":null,"abstract":"<p><strong>Importance: </strong>Climate change and pollution are major health threats that have the potential to worsen the burden of common diseases, such as atopic dermatitis, that are affected by the environment.</p><p><strong>Objective: </strong>To summarize and assess the certainty of evidence on associations between environmental factors and atopic dermatitis outcomes.</p><p><strong>Data sources: </strong>MEDLINE, EMBASE, and Cochrane databases were systematically searched from inception to June 28, 2024.</p><p><strong>Study selection: </strong>Studies included observational studies (cohort, case-control, and cross-sectional) that assessed the association observational studies that assessed associations between climate conditions (eg, ambient air pollution, weather, and climate) and atopic dermatitis outcomes in adults 18 years and older. Searches combined Medical Subject Heading terms and keywords for atopic dermatitis and each environmental factor, with no language, date, or geographical restrictions.</p><p><strong>Data extraction and synthesis: </strong>Data were synthesized using random-effects models, with pooled estimates reported alongside 95% CIs, and the Grading of Recommendations Assessment, Development, and Evaluation was used to assess the certainty of the evidence across outcomes.</p><p><strong>Main outcomes and measures: </strong>Atopic dermatitis prevalence or severity.</p><p><strong>Results: </strong>Of 11 402 citations identified, 42 studies were included. There was an increase in atopic dermatitis outpatient clinic visits for every 10-μg/m3 increase in particulate matter 10 μm in diameter or less (risk ratio [RR], 1.008; 95% CI, 1.003-1.012; high certainty), particulate matter 2.5 μm in diameter or less (RR, 1.013; 95% CI, 0.999-1.027; moderate certainty), sulfur dioxide (RR, 1.029; 95% CI, 1.020-1.039; high certainty), and nitrogen dioxide (RR, 1.014; 95% CI, 0.999-1.030; moderate certainty). Extreme environmental temperatures (hot and cold) were are associated with increased atopic dermatitis-related clinical visits (moderate to high certainty). Higher precipitation, including rain, may be associated with increased atopic dermatitis severity (low certainty), and higher levels of humidity are probably associated with increased atopic dermatitis severity (moderate certainty). Increased duration of sunlight exposure had an uncertain association with atopic dermatitis severity (very low certainty). Secondhand smoking exposure and traffic and industrial plant exposure are probably associated with increased atopic dermatitis prevalence (moderate certainty).</p><p><strong>Conclusions and relevance: </strong>The results of this systematic review and meta-analysis suggest that increased levels of environmental pollutants and temperature extremes are associated with increased population burden of atopic dermatitis. Measures to mitigate pollution and climate change may improve atopic dermatitis outcomes.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"828-839"},"PeriodicalIF":11.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Error in First Authorship.","authors":"","doi":"10.1001/jamadermatol.2025.1895","DOIUrl":"10.1001/jamadermatol.2025.1895","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"890"},"PeriodicalIF":11.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secukinumab and Upadacitinib Treatment for Papillon-Lefèvre Syndrome in 2 Cases.","authors":"Jiaying Li, Zhaoyang Wang, Zigang Xu","doi":"10.1001/jamadermatol.2025.1639","DOIUrl":"10.1001/jamadermatol.2025.1639","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"887-890"},"PeriodicalIF":11.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hundreds of Pruritic Flat-Topped Papules on the Lower Legs.","authors":"Milie M Fang, Lyudmyla Susla, Lynne H Morrison","doi":"10.1001/jamadermatol.2025.1662","DOIUrl":"10.1001/jamadermatol.2025.1662","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"876-877"},"PeriodicalIF":11.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Error in Methods.","authors":"","doi":"10.1001/jamadermatol.2025.2932","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.2932","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":"161 8","pages":"890"},"PeriodicalIF":11.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Comorbidities Among Pediatric Patients With Hidradenitis Suppurativa: A Meta-Analysis.","authors":"Samiha T Mohsen, Emma L Price, Irene Lara-Corrales, Rebecca Levy, Cathryn Sibbald","doi":"10.1001/jamadermatol.2025.1565","DOIUrl":"10.1001/jamadermatol.2025.1565","url":null,"abstract":"<p><strong>Importance: </strong>Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by painful nodules in intertriginous regions that affects many pediatric patients. A significant proportion of patients with pediatric-onset HS may experience comorbidities, including metabolic and psychiatric disorders, adversely impacting their quality of life.</p><p><strong>Objective: </strong>To evaluate the association between HS and relevant comorbidities in pediatric patients and determine the overall pooled prevalence of comorbidities in pediatric patients with HS.</p><p><strong>Data sources: </strong>Embase, PubMed/MEDLINE, and the Cochrane Central Register were searched on February 20, 2025, from database inception with no restrictions.</p><p><strong>Study selection: </strong>Original investigations that reported on prevalence or association between pediatric HS and comorbidities were included. The search included key search terms for pediatric HS and different categories of comorbidities. Two independent authors performed screening and full-text review.</p><p><strong>Data extraction and synthesis: </strong>Extraction was done by 2 authors independently using a template. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence. Data were pooled using random-effects modeling.</p><p><strong>Main outcomes and measures: </strong>Meta-analyses of proportions were completed to estimate pooled prevalence rates, categorizing the data by specific comorbidities (obesity, overweight, anxiety, and others).</p><p><strong>Results: </strong>A total of 19 studies, encompassing 17 267 pediatric patients with HS and 8 259 944 controls, were included. Pediatric patients with HS included in studies were predominantly female (mean of 76.7% [11 683 of 15 232]). The most prevalent comorbidities were acne vulgaris (pooled proportion, 43%; 95% CI, 21-65), obesity (pooled proportion, 37%; 95% CI, 27-46), anxiety (pooled proportion, 18%; 95% CI, 4-31), and hirsutism (pooled proportion, 14%; 95% CI, 6-21). Multiple studies reported on the concurrence of pediatric HS and obesity or depression (GRADE: moderate certainty), and 3 studies reported an association with diabetes (GRADE: low certainty).</p><p><strong>Conclusions and relevance: </strong>In this study, pediatric patients with HS had increased prevalence of chronic medical and psychiatric comorbidities, highlighting the potential benefit of a multidisciplinary approach.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"805-812"},"PeriodicalIF":11.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability of the Ichthyosis Scoring System in Individuals With Skin of Color.","authors":"Angela J Luo, Lisa M Arkin, Sarah Asch, Latanya Benjamin, Anna L Bruckner, María Laura Cossio, Lucia Diaz, Evelyn Lilly, Erin F Mathes, Caroline A Nelson, Elena Pope, Sarika Ramachandran, Dawn H Siegel, Joyce M C Teng, Yunshan Xu, Yanhong Deng, Amy S Paller, Keith A Choate","doi":"10.1001/jamadermatol.2025.1965","DOIUrl":"10.1001/jamadermatol.2025.1965","url":null,"abstract":"<p><strong>Importance: </strong>The Ichthyosis Scoring System (ISS) is a reliable instrument for assessing ichthyosis severity. The ISS's performance in individuals with skin of color (ie, Fitzpatrick IV-VI skin types) remains unknown because it was initially assessed in individuals with Fitzpatrick I to III skin types.</p><p><strong>Objective: </strong>To assess the reliability of the ISS in individuals with Fitzpatrick IV to VI skin types.</p><p><strong>Design, setting, and participants: </strong>In this cross-sectional study, 14 dermatologists used the ISS to rate 94 test photographs, 47 from individuals with Fitzpatrick I to III skin types and 47 from individuals with Fitzpatrick IV to VI skin types. The professional photographs were obtained from the National Registry for Ichthyosis and Related Disorders, which enrolls participants with ichthyosis from referral centers, patient advocacy groups, and self-referral worldwide. Test photographs represented individuals of all phototypes with ichthyosis of all severities. Due to limited comprehensive, high-quality photography among individuals with Fitzpatrick IV to VI skin types, 4 body sites were chosen: upper back, legs, upper arm, and dorsal feet. From August to December 2023, dermatologists independently scored the same test photographs and were blinded to photographic groupings. Data were analyzed in March 2024.</p><p><strong>Main outcomes and measures: </strong>Interrater reliabilities were determined using interrater intraclass correlation coefficients (ICCs) using the two-way random effects model.</p><p><strong>Results: </strong>Of the 61 individuals with ichthyosis represented in the 94 photographs, 28 (46%) were younger than 18 years and 33 (54%) were 18 years and older; 32 (52%) were female and 29 (48%) were male; and 1 (2%) was American Indian, 16 (26%) were Black, 6 (10%) were Hispanic, 1 (2%) was Pacific Islander, 5 (8%) were South Asian, 31 (51%) were White, and 1 (2%) was White and Hispanic. For individuals with Fitzpatrick I to III skin types, scale and erythema ICCs ranged from 0.97 (95% CI, 0.93-0.99) to 0.99 (95% CI, 0.98-1.00) and 0.91 (95% CI, 0.79-0.97) to 0.95 (95% CI, 0.89-0.99), respectively. For individuals with Fitzpatrick IV to VI skin types, scale and erythema ICCs ranged from 0.97 (95% CI, 0.93-0.99) to 0.99 (95% CI, 0.98-1.00) and 0.90 (95% CI, 0.80-0.96) to 0.94 (95% CI, 0.86-0.98), respectively. The overlap of ICC confidence intervals demonstrates ISS reliability across phototypes.</p><p><strong>Conclusions and relevance: </strong>This cross-sectional study shows that the ISS can be applied across phototypes to measure ichthyosis severity. Further studies using full-body photographs would further bolster the ISS's reliability to assess global ichthyosis severity. These findings set the stage for increasing diversity in ichthyosis clinical trials.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"849-854"},"PeriodicalIF":11.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcome Measures and Validation Data Used in Melanoma Research and Routine Practice: A Systematic Review.","authors":"Jake R Thompson, Tayla B McCutcheon, Linda K Martin, Robyn P M Saw, Iris Bartula, Frances Boyle","doi":"10.1001/jamadermatol.2025.2287","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.2287","url":null,"abstract":"<p><strong>Importance: </strong>Patient-reported outcome measures (PROMs) are increasingly used in melanoma research and to guide clinical practice; however, the validation of these PROMs for use in melanoma populations is unknown.</p><p><strong>Objective: </strong>To conduct a systematic review and construct an evidence gap map to identify PROMs that have been used in melanoma research and clinical practice and related melanoma-specific validation data.</p><p><strong>Evidence review: </strong>MEDLINE, Embase, Web of Science Index Medicus, CINAHL, the Cochrane Central Register of Controlled Trials, and PsychINFO were searched in January 2025 including any studies that used a PROM to evaluate outcomes of patients with melanoma published from January 1, 2010, onward to identify instruments relevant to the current era of melanoma diagnosis and treatment.</p><p><strong>Findings: </strong>Of 30 895 abstracts screened, 136 articles detailing 124 studies were included in this review; a total of 32 784 participants were included. There were 52 cross-sectional studies (41%), 31 randomized clinical trials (25%), 23 longitudinal studies (19%), 8 pre-post studies (6%), 6 cohort studies (5%), 1 retrospective analysis (1%), 1 phase 4 trial (1%), 1 protocol (1%), and 1 quasi-experimental trial (1%). A total of 61 studies (49%) included a melanoma treatment, with immunotherapy being the most common (24 [39%]), followed by surgery (7 [11%]), and chemotherapy (7 [11%]). These 124 studies used 110 unique PROMs, with patient emotional/psychological well-being (28 [25%]), health-related quality of life (21 [19%]), and patient self-functioning, efficacy, and coping strategies (20 [18%]) being the most common outcome categories. Only 17 PROMs (15%) had melanoma-specific validation data available, of which only the Functional Assessment of Cancer Therapy-Melanoma questionnaire had data available for all psychometric variables of interest.</p><p><strong>Conclusions and relevance: </strong>In this systematic review, PROMs used in melanoma research and clinical practice were heterogenous, with nearly as many unique instruments identified as studies that used them. Furthermore, few instruments had melanoma-specific validation data available. Future research should aim to address the gaps in melanoma-specific validation data of commonly used PROMs through psychometric evaluation studies to increase researchers' and clinicians' confidence in the performance and accuracy of these measures in melanoma populations.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of New-Onset and Recurrent Depression and Anxiety Among Patients With Hidradenitis Suppurativa.","authors":"Nikolaj Holgersen, Nana Aviaaja Lippert Rosenø, Valdemar Wendelboe Nielsen, Carsten Hjorthøj, Merete Nordentoft, Amit Garg, Andrew Strunk, Jacob P Thyssen, Sandra Feodor Nilsson, Alexander Egeberg, Simon Francis Thomsen","doi":"10.1001/jamadermatol.2025.2298","DOIUrl":"10.1001/jamadermatol.2025.2298","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Patients with hidradenitis suppurativa (HS) have an increased risk of new-onset depression and anxiety, but whether disease severity is a potential independent risk factor remains unknown.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To assess the risk of new-onset and recurrent depression and anxiety among patients with HS and its association with disease severity compared with the background population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This population-based cohort study from 1997 to 2022 included Danish patients with HS who were age and sex matched 1:4 with individuals without HS from the Danish national registries. Data were analyzed from July 18, 2024 to May 20, 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Hospital-diagnosed HS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The main outcomes were first diagnosis of depression or anxiety, as well as first diagnosis of depression and anxiety as separate outcomes after index date. Incidence rates (IRs) and hazard ratios (HRs) were calculated for the first episode of anxiety or depression after baseline using Cox regression models adjusted for demographic and socioeconomic factors as well as comorbidities. Disease severity was defined as treatments received (topicals, systemic nonbiologics, or biologics) and hospitalizations for HS-related surgical procedures (0, 1, 2, or ≥3).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 10 206 patients with HS and 40 125 controls were included (mean [SD] age, 38.0 [13.6] years; 69.9% female in both groups). Throughout the study period, 12.0% received topical only, 55.5% systemic nonbiologic, 6.5% biologic, and 25.9% no HS-related treatments. The adjusted HRs were 1.69 (95% CI, 1.57-1.81; P &lt; .001) for new-onset depression and 1.48 (95% CI, 1.38-1.56; P &lt; .001) for new-onset anxiety. Stratified by treatment, the HRs for either depression or anxiety were 1.62 (95% CI, 1.41-1.85; P &lt; .001) for topicals, 1.61 (95% CI, 1.51-1.72; P &lt; .001) for systemic nonbiologics, and 1.38 (95% CI, 1.01-1.87; P &lt; .05) for biologics. By 0, 1, 2, or 3 or more hospitalizations for HS-related surgical procedures, the HRs were 1.44 (95% CI, 1.36-1.53; P &lt; .001), 1.66 (95% CI, 1.53-2.17), 1.59 (95% CI, 1.33-1.90; P &lt; .001), and 1.60 (95% CI, 1.40-1.85; P &lt; .001), respectively. More patients with HS had a history of depression (7.0% vs 0.3%; P &lt; .001) and anxiety (5.9% vs 0.5%; P &lt; .001) than controls; however, no difference in the risk of recurrent depression (HR, 0.90 [95% CI, 0.62-1.28]; P = .55) or anxiety (HR, 1.22 [95% CI, 0.89-1.66]; P = .22) was observed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion and relevance: &lt;/strong&gt;These findings suggest that patients with HS had an elevated risk of new-onset depression and anxiety. Using treatment- and HS-related surgical procedures as severity markers, no consistent differences in mental health risk across severity levels were observed, emphasizing the need for psychiatric assessment and intervention across all pat","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12311822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}